Suchergebnisse - "Aley, Parvinder K"

PubPharm (69)

1

Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents

enthalten in: iScience | 2023

von Ratcliffe, H. | Tiley, K. | Longet, S. | +38

2

Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults : a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland

enthalten in: The Lancet. Microbe | 2023

von Ramasamy, M. | Kelly, E. | Seegobin, S. | +51

3

Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3) : A randomised controlled trial

enthalten in: The Journal of infection | 2023

von Kelly, E. | Greenland, M. | de Whalley, P. | +31

4

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK : eight-month analyses of the COV-BOOST trial

enthalten in: The Journal of infection | 2023

von Liu, X. | Munro, A. | Wright, A. | +59

5

Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines

enthalten in: The Journal of infection | 2023

von Shaw, R. | Greenland, M. | Stuart, A. | +38

6

Pneumococcal carriage following PCV13 delivered as one primary and one booster dose (1 + 1) compared to two primary doses and a booster (2 + 1) in UK infants

enthalten in: Vaccine | 2023

von Goldblatt, D. | Andrews, N. | Sheppard, C. | +13

7

Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK : Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511

enthalten in: The Journal of infection | 2023

von Liu, X. | Munro, A. | Feng, S. | +56

ErratumFor: J Infect. 2022 Jun;84(6):795-813. - PMID 35405168

8

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222) : 1 year of follow-up of two randomized controlled trials

enthalten in: Clinical and experimental immunology | 2023

von Voysey, M. | Flaxman, A. | Aboagye, J. | +34

9

Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005) : a post-hoc analysis of a randomised, phase 1b-2a trial

enthalten in: The Lancet. Infectious diseases | 2023

von Madhi, S. | Kwatra, G. | Richardson, S. | +34

CommentIn: Lancet Infect Dis. 2023 Mar;23(3):262-263. - PMID 36273489

10

Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2023

von Fidler, S. | Fox, J. | Tipoe, T. | +48

1
2
3
4
5
6
7
Nächster »
[7]